-CONTEPO is a potential first-in-class intravenous antibiotic in U.S. for the treatment of complicated urinary tract infections The NDA for CONTEPO was resubmitted based on the outcome and final ...
Presentation Title: Efficacy and Symptom Resolution by Visit in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of ...
CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic ...
Nabriva Therapeutics threaded the needle from biotech to pharma after it notched its first FDA approval for antibiotic Xenleta back in August. But manufacturing issues for a second antibiotic in ...
-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship -CONTEPO first Qualified Infectious Disease Product to receive NTAP ...
Meitheal, a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic and branded products, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results